POT-4 acetate
Code | Size | Price |
---|
TAR-T9695L-1mg | 1mg | £221.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9695L-5mg | 5mg | £378.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9695L-10mg | 10mg | £550.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9695L-25mg | 25mg | £1,048.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9695L-50mg | 50mg | £1,593.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9695L-100mg | 100mg | £2,277.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
POT-4 acetate inhibits Complement C3 activation. POT-4 acetate can be used for studies about age-related macular degeneration.
CAS:
0
Formula:
C74H106N22O20S2
Molecular Weight:
1687.9
Pathway:
Immunology/Inflammation
Purity:
0.98
SMILES:
O=C(N[C@H](C(N[C@@](C(N[C@H](C(NCC(N[C@H](C(N[C@H]1CC2=CN=CN2)=O)C)=O)=O)CC3=CNC4=CC=CC=C34)=O)([H])CC(O)=O)=O)CCC(N)=O)[C@@H](NC([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC1=O)([H])CCCNC(N)=N)=O)C(N[C@H](C(N)=O)[C@H](O)C)=O)NC([C@@H](NC(C)=O)[C@@H](C)CC)=O)=O)C(C)C)=O)CC5=CN(C)C6=CC=CC=C56.CC(O)=O
Target:
Complement System
References
Robyn Troutbeck, et al. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. Jan-Feb 2012;40(1):18-26.
S. Kaushal, et al. Complement C3 inhibitor POT-4: Clinical Safety of Intravitreal Administration. ARVO Annual Meeting Abstract, 2009 Apr.